GlassScriptPhysician profile
Sampreet Reddy
NPI 1992299622
$4,973.43
in general payments reported to CMS, 2019-2025
25 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $400 · 2023: $604 · 2024: $1,627 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.13 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,418.95 | 2021-2025 | |
| Ucb, INC. | $464.98 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $407.75 | 2024-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $283.79 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $256.64 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $244.84 | 2022-2025 | |
| Galderma Laboratories, L.P. | $232.90 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $196.60 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $185.80 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $173.71 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $153.49 | 2024-2025 | |
| Janssen Biotech, INC. | $141.59 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Vyne Pharmaceuticals INC. | $122.75 | 2021 | |
| Kyowa Kirin, INC. | $107.70 | 2023-2025 | Poteligeo |
| Organon LLC | $101.46 | 2025 | Vtama, Hadlima |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $89.15 | 2025 | Xolair |
| Amgen INC. | $88.50 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $62.01 | 2025 | |
| Pfizer INC. | $61.67 | 2024-2025 | |
| Leo Pharma INC. | $44.42 | 2025 | Anzupgo, Adbry |
| Botanix Sb INC | $40.53 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $37.27 | 2024-2025 | Ycanth |
| Hill Dermaceuticals, INC. | $34.92 | 2025 | Tolak |
| Almirall LLC | $14.93 | 2025 | Klisyri |
| Biowound Solutions, INC. | $7.08 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sampreet Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.